||WO||WO/2014/142828 - CATHETER HAVING MOVABLE TUBULAR STRUCTURE||18.09.2014||
||PCT/US2013/030830||ABBOTT CARDIOVASCULAR SYSTEMS INC.||SHUMER, Daniel, H.|
Catheter including an inner tubular member having a proximal end portion, a distal end portion and an exterior surface. The inner tubular member further has a guidewire lumen defined therein. An outer tubular member is movable relative to the inner tubular member, the outer tubular member has a proximal end, a distal end and an interior surface directed toward the exterior surface of the inner tubular member. A movable tubular structure is disposed between the outer tubular member and the inner tubular member. The movable tubular structure includes a body member having an outer surface with a recess defined therein. The outer tubular member is received within the recess to form a trough along a portion of an exterior surface of the outer tubular member. The trough has a filler disposed therein to couple the outer tubular member to the body member of the movable tubular structure.
||WO||WO/2014/142842 - SUPPLY REGULATION CIRCUIT WITH ENERGY EFFICIENT DIGITAL CONTROL||18.09.2014||
||PCT/US2013/030947||SCHNEIDER ELECTRIC USA, INC.||JEFFERIES, Kevin, M.|
A regulated voltage system with digital control to maintain a regulated voltage supply and protection against overcurrents is disclosed. A regulated supply voltage circuit including a voltage output and a charging capacitor is coupled to a direct current power source. The regulated supply voltage output supplies power to an electrical load. A shunt transistor is coupled between the direct current power source and the regulated supply voltage circuit and ground. A shunt control circuit operates the shunt transistor between an open and closed state. The shunt control circuit includes a cross-coupled bias circuit coupled to a controller. The controller operates the shunt transistor according to a state machine having a first state to close the shunt transistor when the regulated supply voltage exceeds a maximum hysteresis voltage and a second state to open the shunt transistor when the regulated supply voltage is less than a minimum hysteresis voltage.
||WO||WO/2014/142801 - LENGTH AND DIAMETER ADJUSTABLE BALLOON CATHETER FOR DRUG DELIVERY||18.09.2014||
||PCT/US2013/030341||ABBOTT CARDIOVASCULAR SYSTEMS INC.||GIANOTTI, Marc|
Adjustable balloon catheter (100) including an inner tubular member (110) comprising an inflation lumen (130) and a fluid lumen (152) defined therein. An expandable member (140) is coupled to the distal end portion and has an inner chamber defined therein in fluid communication with the inflation lumen, the expandable member transitionable between a deflated and inflated configuration. The expandable member further has an exterior surface, the exterior surface having at least one pore structure (141) defined therein in fluid communication with the fluid lumen. An outer tubular member (120) is movable relative to the inner tubular member, the outer tubular member, the outer tubular member being moveable between an extended position and a retracted position, the outer tubular member being selectively positioned between the extended position and the retracted position to define an exposed length of the working length of the expandable member.
||WO||WO/2014/143080 - METHODS FOR GENERATING PERSONALIZED DIETARY GUIDANCE USING FATTY ACIDS FOR PURPOSES OF REDUCING RISK OF PATHOLOGY||18.09.2014||
||PCT/US2013/035788||BEYOND OBESITY LLC||VOLEK, Jeff, S.|
The present invention relates to methods for managing the risk for pathologies and employing either absolute levels of, or changes over time, for the generation of individual- specific dietary guidance. The method comprises comparing one or more biomarker(s) against thresholds. This comparison provides a score for the individual's risk of developing a pathology, such as type-2 diabetes or weight gain. The biomarkers may be fatty acids, generally, and palmitoleic acid (POA) and/or di-homo gamma-linolenic acid (DGLA) in particular. Samples are collected from the individual and are used to analyze the levels of the biomarkers. The samples can be whole blood, serum, plasma, and buccal mucosa cells, for example. High or increasing levels of the biomarkers indicate that carbohydrate intake is above the individual's metabolic tolerance.
||WO||WO/2014/142978 - LOGIC CHIP INCLUDING EMBEDDED MAGNETIC TUNNEL JUNCTIONS||18.09.2014||
||PCT/US2013/032151||INTEL CORPORATION||LEE, Kevin J.|
An embodiment integrates memory, such as spin-torque transfer magnetoresistive random access memory (STT-MRAM) within a logic chip. The STT-MRAM includes a magnetic tunnel junction (MTJ) with an upper MTJ layer, lower MTJ layer, and tunnel barrier directly contacting the upper MTJ layer and the lower MTJ layer; wherein the upper MTJ layer includes an upper MTJ layer sidewall and the lower MTJ layer includes a lower MTJ sidewall horizontally offset from the upper MTJ layer. Another embodiment includes a memory area, comprising a MTJ, and a logic area located on a substrate; wherein a horizontal plane intersects the MTJ, a first Inter-Layer Dielectric (ILD) material adjacent the MTJ, and a second ILD material included in the logic area, the first and second ILD materials being unequal to one another. In an embodiment the first and second ILDs directly contact one another. Other embodiments are described herein.
||WO||WO/2014/142921 - MODIFIED POLYMERASES FOR IMPROVED INCORPORATION OF NUCLEOTIDE ANALOGUES||18.09.2014||
||PCT/US2013/031694||ILLUMINA, INC.||CHEN, Cheng-Yao|
Presented herein are polymerase enzymes for improved incorporation of nucleotide analogues, in particular nucleotides which are modified at the 3' sugar hydroxyl, as well as methods and kits using the same.
||WO||WO/2014/142810 - PREVENTING MALICIOUS INSTRUCTION EXECUTION||18.09.2014||
||PCT/US2013/030522||INTEL CORPORATION||LI, Xiaoning|
Systems and techniques for preventing malicious instruction execution are described herein. A first instance of an instruction for a graphics processing unit (GPU) may be received. The instruction may be placed in a target list. A notification that the instruction caused a problem with the GPU may be received. The instruction may be moved from the target list to a black list in response to the notification. A second instance of the instruction may be received. The second instance of the instruction may be prevented from executing on the GPU in response to the instruction being on the black list.
||WO||WO/2014/142891 - SELF-CLAMPING HANDRAIL DRIVE||18.09.2014||
||PCT/US2013/031439||OTIS ELEVATOR COMPANY||SRB-GAFFRON, Walter|
Embodiments are directed to a self-clamping handrail device comprising: a belt- handrail compound comprising a first belt, a second belt coupled to the first belt, and a handrail coupled to the second belt, a counter bar and a clamping frame configured to support the belt-handrail compound as the belt-handrail compound passes between the counter bar and the clamping frame, the clamping frame configured to move about a clamping curve based on a tension force applied to the handrail, and the first belt and the second belt applying a normal force to the handrail based at least in part on the tension force.
||WO||WO/2014/143033 - IDENTIFICATION OF CLOSTRIDIUM DIFFICILE CSPC AS A BILE ACID GERMINANT RECEPTOR||18.09.2014||
||PCT/US2013/032464||SORG, Joseph, A.||SORG, Joseph, A.|
The invention provides, inter alia, method of identifying a test compound that binds a germination-related protease-like protein (CspC), e.g., compounds that are agonists or antagonists of germination of a spore of a Clostridium species, such as Clostridium difficile. The invention also provides methods of treating and/or preventing a Clostridium infection in a mammalian subject in need thereof.
||WO||WO/2014/143048 - TISSUE ADHESIVE COATINGS FOR DRUG BALLOON||18.09.2014||
||PCT/US2013/032570||ABBOTT CARDIOVASCULAR SYSTEMS, INC.||PACETTI, Stephen|
A therapeutic formulation is described for a drug delivery balloon comprising a therapeutic formulation which includes a therapeutic agent and an adhesion additive. The adhesion additive promotes adhesion of the therapeutic formulation to a vessel wall of a subject. A system and a method of manufacturing a system including an expandable member having a working length with the therapeutic formulation disposed along at least a portion of the working length is also provided.